Aaron Andrew Heigaard Smith

Aaron Andrew Heigaard Smith

Auto-generated profile, based on publicly available information

Aaron Andrew Heigaard Smith

Department of Cardiovascular Medicine, Sanford Health North, Fargo, North Dakota, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Trends in Cardiovascular Medicine
Verified
Journal Article
Open access
JKJacquelyn Kulinski
Jacquelyn Kulinski
EOErnest Kwesi Ofori
Ernest Kwesi Ofori
AVAlexis Visotcky
Alexis Visotcky
ASAaron Smith
Aaron Smith
RSRodney Sparapani
Rodney Sparapani
JFJerome L. Fleg
Jerome L. Fleg
Although music is predominantly utilized for religious, enjoyment or entertainment purposes, it is gradually emerging as a promising non-pharmacological intervention for improving health outcomes in both healthy and diseased populations, especially in those with cardiovascular diseases. As such, music of various genres and types has been postulated to possess features that stimulate or inhibit the autonomic nervous system, which leads to variable effects on cardiovascular function. However, music intervention has not been adequately explored as a cardiovascular therapeutic modality due to the lack of extensive studies with quality methodology. Thus, the aim of this systematic review is to explore the available literature on the effect of music on the cardiovascular system, discuss the limitations of current research, and suggest future directions in this field.

1 May 2022 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
DMDivyanshu Mohananey
Divyanshu Mohananey
MAMichael Aljadah
Michael Aljadah
ASAaron A.H. Smith
Aaron A.H. Smith
JHJeremiah F. Haines
Jeremiah F. Haines
SPSahishnu Patel
Sahishnu Patel
HRHarish Ramakrishna
Harish Ramakrishna

1 November 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ASAaron A.H. Smith
Aaron A.H. Smith
MWMoses Wananu
Moses Wananu
MCMichelle D. Carlson
Michelle D. Carlson

1 October 2020 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Open access
PDF file
ASAaron Andrew Heigaard Smith
Aaron Andrew Heigaard Smith
ELErin Luxenberg
Erin Luxenberg
RMRoberta Meyers
Roberta Meyers

11 March 2026 in Heart
Verified
Journal Article
Closed access
PDF file
AAAwais Aslam
Awais Aslam
WKWahab Khan
Wahab Khan
SHSyed H Haq
Syed H Haq
INIfrah Nadeem
Ifrah Nadeem
SKSalman J Khan
Salman J Khan
ASAaron Andrew Heigaard Smith
Aaron Andrew Heigaard Smith
Cardiac sarcoidosis (CS) is a rare and complex disease that requires a multidisciplinary approach for diagnosis and treatment. The diagnosis of CS can be confirmed by histological examination of non-caseating granulomas in cardiac or extracardiac tissue, along with supportive clinical and imaging findings. Symptoms are often non-specific, and the yield of endomyocardial biopsy is low due to the patchy nature of cardiac involvement—thus, many cases are not straightforward to diagnose, especially when pulmonary or extracardiac features are absent. Modern non-invasive imaging modalities have unique strengths in assessing the myocardium’s structure, function, perfusion, inflammation and fibrosis—abnormalities of all these features exist in CS in varying degrees and can be integrated to assist in the diagnosis. Echocardiography is universally used as the initial imaging test when CS is suspected and provides information on cardiac structure and function, but is limited by inadequate tissue characterisation and differentiation from other infiltrative or restrictive cardiomyopathies. Positron emission tomography (PET) and cardiovascular magnetic resonance (CMR) have good accuracy in diagnosing CS. With current tissue characterisation techniques, such as T1 and T2 parametric mapping, CMR imaging can detect subclinical or early CS. While CMR has better overall prognostic utility for arrhythmic risk and cardiac mortality, fluorodeoxyglucose (FDG)-PET is superior in monitoring disease activity and guiding anti-inflammatory therapy. Hybrid FDG-PET/CMR imaging is a newer, complementary approach that is being increasingly used in centres of excellence. It combines the unique strengths of both modalities, thereby achieving superior sensitivity and specificity.

3 March 2020 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASAaron A. H. Smith
Aaron A. H. Smith
OIOmer J. Iqbal
Omer J. Iqbal